✦ LIBER ✦

646 - Mitoxantrone (N) vs. 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as first line therapy in high-risk metastatic breast cancer

✍ Scribed by G. von minckwitz; E. Heldemann; R. Souchon; H. Samonigg; W.D. Hirschmann; H. Bodenstein; A. Schindler; M. Schulze; H. Clemens; M. König; A. Scharl; J.Th. Flscher; M. Kaufmann

Book ID: 117664894
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 416 KB
Volume: 33
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)85219-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cyclophosphamide, epirubicin, high-dose

Cyclophosphamide, epirubicin, high-dose folinic acid and 5-fluorouracil (super-FEC) as first-line chemotherapy for advanced breast cancer: Preliminary results

✍ Zaniboni, Alberto; Simoncini, Edda; Marpicati, Patrizia; Montini, Elisabetta; Fe 📂 Article 📅 1989 🏛 Elsevier Science ⚖ 553 KB

22 First interim analysis of a randomize

22 First interim analysis of a randomized trial comparing capecitabine/epirubicin/cyclophosphamide (XEC) vs 5-FU/epirubicin/cyclophosphamide (FEC) as adjuvant therapy for medium- or high-risk early breast cancer (EBC)

✍ Z. Shao; B. Huang; J. Zhang; S. Zhou; P. He; D. Chen; S. Cui; C. Ren; L. Cai; J. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Gemcitabine, epirubicin and paclitaxel (

Gemcitabine, epirubicin and paclitaxel (GET) vs. 5-fluorouracil, epirubicin and cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer: interim toxicity analysis of a randomised, multicenter phase iii trial of the Central European Cooperative Oncology Group (CECOG)

✍ T. Brodowicz; S. Beslija; J. Cervek; Z. Mrsic-Krmpotic; I. Tchernozemsky; C. Wil 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 166 KB